KRAS and neoplasm: The finding that the Kras-mutation is largely dependent upon estrogen to induce tumor development is an exciting result that may have direct clinical applicability for patients with non-HPV anal SCC that have poorly understood pathogenesis and are known to exhibit resistance to standard of care therapy [5].